Jeddah, Saudi Arabia

Thikryat Neamatallah


Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2020-2022

Loading Chart...
4 patents (USPTO):Explore Patents

Title: Thikryat Neamatallah: Innovator in Cancer Treatment

Introduction

Thikryat Neamatallah is a prominent inventor based in Jeddah, Saudi Arabia. He has made significant contributions to the field of cancer treatment through his innovative research and development of cytotoxic compounds. With a total of 4 patents, his work focuses on creating effective pharmaceutical compositions for treating various types of cancer.

Latest Patents

Neamatallah's latest patents include groundbreaking work on chemotherapeutic oxazolone derivatives and pharmaceutical compositions thereof. These patents describe cytotoxic compounds that contain a phenyl core, amide link(s), and either an imidazolinone or a propenamide moiety. The compounds have shown effectiveness against breast, prostate, and leukemia cancer cell lines by dual inhibition of Src kinases and tubulin. His research emphasizes the importance of these compounds in developing new methods for cancer treatment.

Career Highlights

Thikryat Neamatallah is affiliated with King Abdulaziz University, where he conducts his research and collaborates with fellow scientists. His dedication to advancing cancer treatment has positioned him as a key figure in the field of pharmaceutical innovation. His work not only contributes to scientific knowledge but also aims to improve patient outcomes in cancer therapy.

Collaborations

Neamatallah has worked alongside notable colleagues such as Moustafa Elsayed El-Araby and Abdelsattar Mansour Omar. Their collaborative efforts have further enhanced the research and development of effective cancer treatments.

Conclusion

Thikryat Neamatallah's contributions to cancer treatment through his innovative patents and research at King Abdulaziz University highlight his commitment to improving healthcare. His work continues to pave the way for new therapeutic options in the fight against cancer.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…